Title:
医薬処方物
Document Type and Number:
Japanese Patent JP6736656
Kind Code:
B2
Abstract:
This invention relates to pharmaceutical formulations comprising 1-(2-thien-2′-yl-2-oxo-ethyl)-3-(methanesulfonyl hydrazine carbonyl) pyridinium, its pharmaceutically acceptable salts, salt-cocrystals and co-crystals, particularly 1-(2-thien-2′-yl-2-oxo-ethyl)-3-5(methanesulfonyl hydrazine carbonyl) pyridinium chloride. The formulations are suitable for oral administration and also comprise a permeability enhancer or a suitable base or a mixture thereof. The formulations of this invention are for treating diseases associated with advanced glycation end products.
Inventors:
Dat, Chaitanya
Abraham, Jaya
Mishra, Vivek
Kesar crocodile, Amit
Gupta, Ramesh, Chandra
Deshpande, Shireesh
Zambard, sitar, Kumar
Mathur, Anoop
Kotecha, Jigneche
Ratad, Sachin
Patel, Manish
Chordary, anita
Abraham, Jaya
Mishra, Vivek
Kesar crocodile, Amit
Gupta, Ramesh, Chandra
Deshpande, Shireesh
Zambard, sitar, Kumar
Mathur, Anoop
Kotecha, Jigneche
Ratad, Sachin
Patel, Manish
Chordary, anita
Application Number:
JP2018503835A
Publication Date:
August 05, 2020
Filing Date:
April 05, 2016
Export Citation:
Assignee:
TORRENT PHARMACEUTICALS LIMITED
International Classes:
A61K31/4436; A61K47/02; A61K47/12; A61K47/18; A61K47/26
Domestic Patent References:
| JP2003511369A | ||||
| JP2013514976A | ||||
| JP2009023932A | ||||
| JP2012526103A | ||||
| JP2012067115A |
Other References:
YAKUGAKU ZASSHI,2010年,Vol.130,p.1123-1127
Biomaterials,2013年,Vol.34,p.275-282
Biomaterials,2013年,Vol.34,p.275-282
Attorney, Agent or Firm:
Kiyoji Kuzuwa